{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:52:23Z","timestamp":1791312743837,"version":"4.3.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"25-26","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1016\/j.vaccine.2004.02.034","type":"journal-article","created":{"date-parts":[[2004,4,10]],"date-time":"2004-04-10T07:53:41Z","timestamp":1081583621000},"page":"3358-3366","source":"Crossref","is-referenced-by-count":63,"title":["Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB\/c mice from a lethal intranasal poxvirus challenge"],"prefix":"10.1016","volume":"22","author":[{"given":"D.J","family":"Pulford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Gates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.H","family":"Bridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.H","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Ulaeto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2004.02.034_BIB1","unstructured":"Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. Smallpox and its eradication. WHO; 1988."},{"key":"10.1016\/j.vaccine.2004.02.034_BIB2","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/414748a","article-title":"Transmission potential of smallpox in contemporary populations","volume":"414","author":"Gani","year":"2001","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.vaccine.2004.02.034_BIB3","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3201\/eid0706.010607","article-title":"Modeling potential responses to smallpox as a bioterrorist weapon","volume":"7","author":"Meltzer","year":"2001","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.vaccine.2004.02.034_BIB4","first-page":"669","article-title":"An airborne outbreak of smallpox in a German hospital and its significance with respect to other recent outbreaks in Europe","volume":"43","author":"Wehrle","year":"1970","journal-title":"Bull. World Health Organisation"},{"issue":"22","key":"10.1016\/j.vaccine.2004.02.034_BIB5","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1001\/jama.281.22.2127","article-title":"Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense","volume":"281","author":"Henderson","year":"1999","journal-title":"J. Am. Med. Assoc."},{"issue":"17","key":"10.1016\/j.vaccine.2004.02.034_BIB6","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1056\/NEJMra020025","article-title":"Diagnosis and management of smallpox","volume":"346","author":"Breman","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.vaccine.2004.02.034_BIB7","first-page":"13","article-title":"Human monkeypox","volume":"27","author":"Jezek","year":"1983","journal-title":"J. Hyg. Epidemiol. Microbiol. Immunol."},{"issue":"6","key":"10.1016\/j.vaccine.2004.02.034_BIB8","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1093\/oxfordjournals.aje.a114328","article-title":"Four generations of probable person-to-person transmission of human monkeypox","volume":"123","author":"Jezek","year":"1986","journal-title":"Am. J. Epidemiol."},{"issue":"1","key":"10.1016\/j.vaccine.2004.02.034_BIB9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1001\/jama.290.1.23","article-title":"Monkeypox outbreak a reminder of emerging infections vulnerabilities","volume":"290","author":"Stephenson","year":"2003","journal-title":"J. Am. Med. Assoc."},{"issue":"6","key":"10.1016\/j.vaccine.2004.02.034_BIB10","first-page":"457","article-title":"Comparison between killed subunit influenza vaccines and whole virion preparations: study of reactions and protective efficacy in children and adults","volume":"58","author":"Profeta","year":"1980","journal-title":"Boll. Ist. Sieroter. Milan"},{"key":"10.1016\/j.vaccine.2004.02.034_BIB11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1146\/annurev.pu.09.050188.001223","article-title":"Viral vaccines and antivirals: current use and future prospects","volume":"9","author":"Parkman","year":"1988","journal-title":"Annu. Rev. Public Health"},{"issue":"10","key":"10.1016\/j.vaccine.2004.02.034_BIB12","first-page":"992","article-title":"Recombinant DNA technology for the preparation of subunit vaccines","volume":"181","author":"Bachrach","year":"1982","journal-title":"J. Am. Vet. Med. Assoc."},{"issue":"11","key":"10.1016\/j.vaccine.2004.02.034_BIB13","doi-asserted-by":"crossref","first-page":"5910","DOI":"10.1128\/JVI.65.11.5910-5920.1991","article-title":"Extracellular vaccinia virus formation and cell-to-cell virus transmission are prevented by deletion of the gene encoding the 37,000-Dalton outer envelope protein","volume":"65","author":"Blasco","year":"1991","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.vaccine.2004.02.034_BIB14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1099\/0022-1317-50-1-89","article-title":"Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia","volume":"50","author":"Payne","year":"1980","journal-title":"J. Gen. Virol."},{"issue":"13","key":"10.1016\/j.vaccine.2004.02.034_BIB15","doi-asserted-by":"crossref","first-page":"7544","DOI":"10.1073\/pnas.95.13.7544","article-title":"Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope","volume":"95","author":"Vanderplasschen","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"1","key":"10.1016\/j.vaccine.2004.02.034_BIB16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1006\/viro.1998.9516","article-title":"Neutralizing and protective antibodies directed against vaccinia virus envelope antigens","volume":"254","author":"Galmiche","year":"1999","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.vaccine.2004.02.034_BIB17","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1006\/viro.1999.0096","article-title":"DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge","volume":"266","author":"Hooper","year":"2000","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.vaccine.2004.02.034_BIB18","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0042-6822(02)00038-7","article-title":"Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates","volume":"306","author":"Hooper","year":"2003","journal-title":"Virology"},{"issue":"8","key":"10.1016\/j.vaccine.2004.02.034_BIB19","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0966-842X(96)10051-2","article-title":"Receptors for gamma-interferon encoded by poxviruses: implications for the unknown origin of vaccinia virus","volume":"4","author":"Alcami","year":"1996","journal-title":"Trends Microbiol."},{"issue":"8","key":"10.1016\/j.vaccine.2004.02.034_BIB20","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1128\/JVI.69.8.4633-4639.1995","article-title":"Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity","volume":"69","author":"Alcami","year":"1995","journal-title":"J. Virol."},{"issue":"11","key":"10.1016\/j.vaccine.2004.02.034_BIB21","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1086\/340517","article-title":"Primary induction of human CD8+ cytotoxic T lymphocytes and interferon-gamma-producing T cells after smallpox vaccination","volume":"185","author":"Ennis","year":"2002","journal-title":"J. Infect. Dis."},{"issue":"10","key":"10.1016\/j.vaccine.2004.02.034_BIB22","doi-asserted-by":"crossref","first-page":"7404","DOI":"10.1128\/JVI.71.10.7404-7420.1997","article-title":"Vaccinia virus membrane proteins p8 and p16 are cotranslationally inserted into the rough endoplasmic reticulum and retained in the intermediate compartment","volume":"71","author":"Salmons","year":"1997","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.vaccine.2004.02.034_BIB23","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0042-6822(90)90477-9","article-title":"Inducible gene expression from vaccinia virus vectors","volume":"177","author":"Rodriguez","year":"1990","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2004.02.034_BIB24","first-page":"30","article-title":"Insertion mutants of the vaccinia virus. The effect of inactivating E7R and D8L genes on the biological properties of the virus","volume":"2","author":"Chernos","year":"1993","journal-title":"Mol. Gen. Mikrobiol. Virusol."},{"issue":"2","key":"10.1016\/j.vaccine.2004.02.034_BIB25","first-page":"151","article-title":"Amino acid sequence determination of vaccinia virus immunodominant protein p35 and identification of the gene","volume":"2","author":"Chertov","year":"1991","journal-title":"Biomed. Sci."},{"issue":"12","key":"10.1016\/j.vaccine.2004.02.034_BIB26","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1128\/JVI.64.12.5988-5996.1990","article-title":"Use of a cell-free system to identify the vaccinia virus L1R gene product as the major late myristylated virion protein M25","volume":"64","author":"Franke","year":"1990","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.vaccine.2004.02.034_BIB27","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1128\/JVI.70.6.3753-3762.1996","article-title":"Extracellular vaccinia virus envelope glycoprotein encoded by the A33R gene","volume":"70","author":"Roper","year":"1996","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.vaccine.2004.02.034_BIB28","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1128\/JVI.66.3.1610-1621.1992","article-title":"Identification and characterization of an extracellular envelope glycoprotein affecting vaccinia virus egress","volume":"66","author":"Duncan","year":"1992","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.vaccine.2004.02.034_BIB29","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1099\/0022-1317-71-6-1293","article-title":"Biological and immunological characterization of influenza virus haemagglutinin expressed from the haemagglutinin locus of vaccinia virus","volume":"71","author":"Itamura","year":"1990","journal-title":"J. Gen. Virol."},{"issue":"2","key":"10.1016\/j.vaccine.2004.02.034_BIB30","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/0042-6822(92)90535-W","article-title":"A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope","volume":"188","author":"Engelstad","year":"1992","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.vaccine.2004.02.034_BIB31","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1006\/viro.1994.1542","article-title":"Vaccinia virus gene A36R encodes a M(r) 43\u201350 K protein on the surface of extracellular enveloped virus","volume":"204","author":"Parkinson","year":"1994","journal-title":"Virology"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X04002063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X04002063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T19:27:08Z","timestamp":1585682828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X04002063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":31,"journal-issue":{"issue":"25-26","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["S0264410X04002063"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2004.02.034","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2004,9]]}}}